Scarica l'app Stockscreener
166.29
0.03%
0.05
Dopo l'orario di chiusura:
166.29
Precedente Chiudi:
$166.24
Aprire:
$165.5
Volume 24 ore:
859.12K
Relative Volume:
0.74
Capitalizzazione di mercato:
$10.10B
Reddito:
$4.16B
Utile/perdita netta:
$-368.48M
Rapporto P/E:
-27.39
EPS:
-6.0701
Flusso di cassa netto:
$1.28B
1 W Prestazione:
+1.92%
1M Prestazione:
+1.59%
6M Prestazione:
+46.73%
1 anno Prestazione:
+22.78%
Intervallo 1D:
$165.08
$168.19
Intervallo di 1 settimana:
$161.38
$168.19
Portata 52W:
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
166.29 | 10.10B | 4.16B | -368.48M | 1.28B | -6.0701 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
LSV Asset Management Sells 41,884 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire Inc.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? - Yahoo Finance
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 - PR Newswire UK
Essex Investment Management Co. LLC Invests $2.70 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) Valuation After HERIZON GEA Trial Upside And Planned 2026 sBLA Filing - simplywall.st
Renaissance Group LLC Sells 7,254 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Lupin Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral SolutionLupin | Press Release - lupin.com
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How HERIZON-GEA’s First-Line GEA Data And sBLA Plan At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story - simplywall.st
The Best Biotech Stocks to Buy - Morningstar
Allianz Asset Management GmbH Purchases 30,537 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Zacks Research Brokers Lower Earnings Estimates for JAZZ - MarketBeat
New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings - Yahoo Finance
What is Zacks Research's Estimate for JAZZ Q1 Earnings? - MarketBeat
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial - Insider Monkey
Strs Ohio Sells 14,393 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals plc (JAZZ): Investor Outlook with a 32% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
What is the target price for Jazz Pharmaceuticals plc stockMarket Risk Analysis & High Win Rate Trade Tips - baoquankhu1.vn
Autistic Disorder Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Bioscienc - Barchart.com
Autistic Disorder Pipeline 2025: Therapies Under - openPR.com
Top Investors’ Stock Portfolio: 10 Mid-cap Stocks To Buy - Insider Monkey
The Truth About Jazz Pharmaceuticals: Why Wall Street Suddenly Can’t Shut Up - AD HOC NEWS
Is Jazz Pharmaceuticals (JAZZ) Offering An Opportunity After Recent Share Price Pullback - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) Offering Opportunity After A 32% One Year Share Price Gain - simplywall.st
These 4 Measures Indicate That Jazz Pharmaceuticals (NASDAQ:JAZZ) Is Using Debt Reasonably Well - 富途牛牛
Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Great Lakes Advisors LLC - MarketBeat
Lewy Body Dementia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt - Barchart.com
Mitsubishi UFJ Trust & Banking Corp Raises Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Weekly: Is ADPT a good ESG investmentStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? - Finviz
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Stock Analysis: Unpacking A Promising 28% Upside Potential - DirectorsTalk Interviews
How Boehringer Ingelheim Oncology Collaboration Could Shape Jazz Pharmaceuticals' (JAZZ) Dual HER2 Strategy - simplywall.st
Universal Beteiligungs und Servicegesellschaft mbH Cuts Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After New Boehringer Ingelheim Oncology Collaboration - simplywall.st
Aug Update: Should I invest in Kaltura Inc before earningsEarnings Miss & Intraday High Probability Alerts - baoquankhu1.vn
Dip Buying: Why is Jazz Pharmaceuticals plc stock going upEarnings Risk Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Lmcg Investments LLC Trims Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Mood: Will Jazz Pharmaceuticals plc benefit from green energy policiesTrade Exit Report & Community Consensus Stock Picks - baoquankhu1.vn
Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration - Yahoo Finance
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization? - simplywall.st
New York State Teachers Retirement System Sells 9,223 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum - simplywall.st
JPM26: Jazz sells PRV for $200m, targets deals in 2026 - Pharmaceutical Technology
JAZZJazz Pharmaceuticals Plc Latest Stock News & Market Updates - Stock Titan
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate - BioSpace
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Jazz Pharmaceuticals Soars with Promising HERIZON-GEA-01 Results - timothysykes.com
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):